Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine.
3rd ed. Berlin, Germany: Springer-Verlag; 1998:215.
Muriel P, Garciapina T, Perez-Alvarez V, et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage.
J Appl Toxicol.
1992;12:439-442.
Paulova J, Dvorak M, Kolouch F, et al. Verification of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs [in Czech].
Vet Med (Praha).
1990;35:629-635.
Skakun NP, Moseichuk IP. Clinical pharmacology of legalon [in Russian].
Vrach Delo.
1988;5:5-10.
Tuchweber B, Sieck R, Trost W. Prevention of silybin of phalloidin-induced acute hepatotoxicity.
Toxicol Appl Pharmacol.
1979;51:265-275.
Boari C, Montanari FM, Galletti GP, et al. Toxic occupational liver diseases. Therapeutic effects of silymarin [in Italian].
Minerva Med.
1981;72:2679-2688.
Szilard S, Szentogyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents.
Acta Med Hung.
1988;45:249-256.
La Grange L, Wang M, Watkins R, et al. Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver.
J Ethnopharmacol.
1999;65:53-61.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine,
3rd ed. Berlin, Germany: Springer-Verlag; 1998:216.
Hikino H, Kiso Y. Natural products for liver disease.
Econ Med Plant Res.
1988;2:39-72.
Muzes G, Deak G, Lang I, et al. Effects of silymarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease [in Hungarian].
Orv Hetil.
1990;131:863-866.
Allain H, Schuck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.
Dement Geriatr Cogn Disord.
1999;10:181-185.
Giannola C, Buogo F, Forestiere G, et al. A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency [in Italian].
Clin Ther.
1985;114:129-135.
Sonnenbichler J, Scalera F, Sonnenbichler I, et al. Stimulatory effects of silibinin and silicristin from the milk thistle
Silybum marianum
on kidney cells.
J Pharmacol Exp Ther.
1999;290:1375-1383.
Zi X, Feyes DK, and Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468.
Clin Cancer Res.
1998;4:1055-1064.
Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.
Int J Clin Pharmacol Ther.
2002;40:2-8.
Berenguer J, Carrasco D. Double-blind trial of silymarin vs. placebo in the treatment of chronic hepatitis.
Munch Med Wochenschr.
1977;119:240-260.
Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB 1016) in chronic active hepatitis.
Int J Clin Pharmacol Ther Toxicol.
1993;31:456-460.
Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: Experience with ursodeoxycholic acid and silymarin in chronic liver disease.
Acta Physiol Hung.
1992;80:363-367.
Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [translated from German].
Med Klin.
1978;73:1060-1065.
Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial [translated from German].
Med Klin.
1977;72:513-518.
Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [translated from German].
Med Klin.
1978;73:1060-1065.
Salmi HA, Sarna S. Effect of silymarin on chemical, functional and morphological alterations of the liver. A double-blind controlled study.
Scand J Gastroenterol.
1982;17:517-521.
Feher J, Desk G, Muzes G, et al. Liver protective action of silymarin therapy in chronic alcoholic liver diseases [in Hungarian].
Orv Hetil.
1989;130:2723-2727.
Fintelmann V, Albert A. Proof of the therapeutic efficacy of LegalonŴ for toxic liver illnesses in a double-blind trial [translated from German].
Therapiewoche.
1980;30:5589-5594.
Trinchet JC, Coste T, Levy VG, et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients [translated from French].
Gastroenterol Clin Biol.
1989;13:120-124.
Bunout D, Hirsch SB, Petermann MT, et al. Controlled study of the effect of silymarin on alcoholic liver disease [translated from Spanish].
Rev Med Chil.
1992;120:1370-1375.
Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
J Hepatol.
1989;9:105-113.
Benda L, Dittrich H, Ferenzi P, et al. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis [translated from German].
Wien Klin Wochenschr.
1980;92:678-683.
Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
J Hepatol.
1998;28:615-621.
Brinker F.
Herb Contraindications and Drug Interactions: With Appendices Addressing Specific Conditions and Medicines.
2nd ed. Sandy, OR: Eclectic Medical Publications; 1998:103.
Palasciano G, Portincasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs.
Curr Ther Res.
1994;55:537-545.
Allain H, Schuck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.
Dement Geriatr Cogn Disord.
1999;10:181-185.
Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
Arzneimittelforschung.
1992;42:964-968.
Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex in healthy human subjects.
Eur J Drug Metab Pharmacokinet.
1990;15:333-338.
Awang D. Milk thistle.
Can Pharm J.
1993;126:403-404.
Albrecht M, Frerick H, Kuhn U, et al. Therapy of toxic liver pathologies with Legalon [in German].
Z Klin Med.
1992;47:87-92.
Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (
Silybum marianum).
Med J Aust.
1999;170:218-219.
Giannola C, Buogo F, Forestiere G, et al. A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency [in Italian].
Clin Ther.
1985;114:129-135.
Kim DH, Jin YH, Park JB, et al. Silymarin and its components are inhibitors of beta-glucuronidase.
Biol Pharm Bull.
1994;17:443-445.
Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.
Int J Clin Pharmacol Ther.
2002;40:2-8.
Lang I, et al. Hepatoprotective and immunological effects of antioxidant drugs.
Tokai J Exp Clin Med.
1990;15:123-127.
Lang I, et al. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.
Ital J Gastroenterol.
1990;22:283-287.
Gordon A, Hobbs DA, Bowden DS et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
J Gastroenterol Hepatol.
2006;21:275-80.
Angulo P, Patel T, Jorgensen RA et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Hepatology.
2000;32:897-900.
Torres M, Rodriguez-Serrano F, Rosario DJ et al. Does Silybum marianum play a role in the treatment of chronic hepatitis C?
P R Health Sci J.
2006;23:69-74
Huseini HF, Larijani B, Heshmat R et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
Phytother Res.
2006 Oct 30. [Epub ahead of print]
Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.
Integr Cancer Ther.
2007;6:110-119.
Rambaldi A, Jacobs B, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Cochrane Database Syst Rev.
2007;CD003620.
Berardesca E, Cameli N, Cavallotti C, et al. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation.
J Cosmet Dermatol.
2008;7:8-14.
Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin.
Forsch Komplement Med.
2008;15:9-20.
Sayyah M, Boostani H, Pakseresht S, Malayeri A.
Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder.
Prog Neuropsychopharmacol Biol Psychiatry.
2010;34(2):362-365.
El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.
Phytomedicine.
2009;16(5):391-400.
Hutchinson C, Bomford A, Geissler CA.
The iron-chelating potential of silybin in patients with hereditary haemochromatosis.
Eur J Clin Nutr.
2010;64(10):1239-1241.
Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes.
J Ethnopharmacol.
2011;137(3):1328-1333.